NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has been granted conditional approval for its fluorescence in situ hybridization (FISH)-based ROS1 lung cancer biomarker assay from the New York State Department of Health (NYSDOH).

With the decision, the company said its ROS1 FISH assay, which was acquired through Rosetta's purchase of PersonalizeDx earlier this year, is now available in all 50 US states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.